[A21-170] Daratumumab (multiple myeloma) - Addendum to Commission A21-101

Last updated 03.02.2022

Project no.:

Commission awarded on 21.12.2021 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


Adult patients with multiple myeloma

Result of dossier assessment:

Unchanged after addendum:

  • Patients who have already received 1 prior therapy with a proteasome inhibitor and lenalidomide and who were refractory to lenalidomide: added benefit not proven.
  • Patients who have already received ≥ 2 prior therapies containing lenalidomide and a proteasome inhibitor and who showed disease progression under or after the last therapy: added benefit not proven.

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-02-03 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form